Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

27.28 +0.42 (+1.56%)

Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

34 35 Next >

Unpacking the Latest Options Trading Trends in Viking Therapeutics ↗

October 29, 2024

Via Benzinga

Here's How Much $100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth Today ↗

October 28, 2024

Via Benzinga

Could Buying This Weight Loss Stock Be Like Investing in Novo Nordisk At The Dawn of The GLP-1 Revolution? ↗

October 27, 2024

Novo Nordisk dominates diabetes treatment and obesity care, but one clinical-stage pharma company could be the next breakout star.

Via The Motley Fool

S&P 500, Nasdaq Rise Sharply Ending 3-Day Losing Streak; Viking Therapeutics Surge, While Capri’s Shares Slump ↗

October 25, 2024

US benchmark equity averages rose on Friday as the market ended a three-day losing streak.

Via Talk Markets

Topics Stocks

Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Review ↗

October 25, 2024

The major indexes were mixed for the week.

Via Investor's Business Daily

3 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 24, 2024

Via Benzinga

Why Viking Therapeutics Stock Soared by Nearly 21% on Thursday ↗

October 24, 2024

The company provided clear evidence that it has plenty of resources to continue developing a potential blockbuster drug.

Via The Motley Fool

UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday ↗

October 24, 2024

Via Benzinga

How Viking Therapeutics Just Dealt A Blow To Eli Lilly's Obesity Triplet ↗

October 24, 2024

Viking is planning to file with the FDA next year to begin testing a quadruple approach to weight loss.

Via Investor's Business Daily

3 Growth Stocks That Have Generated 1,000% Returns Since the Last Presidential Election (and They've All Outperformed Nvidia) ↗

October 24, 2024

Regardless of who wins the presidency, investors are better off focusing on top growth stocks.

Via The Motley Fool

An Overview of Viking Therapeutics's Earnings ↗

October 22, 2024

Via Benzinga

Market Whales and Their Recent Bets on VKTX Options ↗

October 22, 2024

Via Benzinga

Here's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years ↗

October 10, 2024

Via Benzinga

Viking Therapeutics Unusual Options Activity ↗

October 08, 2024

Via Benzinga

Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition ↗

October 23, 2024

Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition.

Via Benzinga

Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains? ↗

October 22, 2024

Viking Therapeutics (VKTX) set to report Q3 earnings amid high expectations, thanks to promising weight-loss drug candidate. Stock up 240% YTD.

Via Benzinga

Viking Therapeutics Gives Investors Another Reason to Remain Bullish on Its Future ↗

October 17, 2024

Viking recently announced the results of an early-stage clinical trial for VK0214.

Via The Motley Fool

10 Health Care Stocks With Whale Alerts In Today's Session ↗

October 16, 2024

Via Benzinga

Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade ↗

October 14, 2024

The analyst is closely watching MariTide, a potential monthly injection to treat obesity.

Via Investor's Business Daily

$100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth This Much Today ↗

September 27, 2024

Via Benzinga

Where Will Viking Therapeutics Be in 5 Years? ↗

October 14, 2024

We could be witnessing the birth of a major player in the biotech industry.

Via The Motley Fool

Better Biotech Stock to Buy With $1,500 Right Now: Viking Therapeutics vs. Summit Therapeutics ↗

October 13, 2024

It's hard to go wrong with either company, but one is more appealing.

Via The Motley Fool

The Ultimate Biotech Stock to Buy With $100 Right Now ↗

October 12, 2024

This company is operating in one of today's hottest markets.

Via The Motley Fool

Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names ↗

October 11, 2024

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.

Via Benzinga

Viking Therapeutics Reveals Encouraging Data From Genetic Disorder Drug Study, Analyst Says Focus On Orphan Disease Broadens Viking's Potential Revenue Streams ↗

October 09, 2024

Viking Therapeutics' VK0214 Phase 1b trial in X-ALD patients showed significant reductions in VLCFAs and other lipids, while demonstrating safety. Analyst sees potential revenue upside with continued...

Via Benzinga

2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts ↗

October 07, 2024

The investment bank analysts who follow these stocks think they can soar even further, with some caveats.

Via The Motley Fool

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer ↗

October 04, 2024

Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention.

Via Investor's Business Daily

Why Viking Therapeutics Stock Topped the Market Today ↗

September 30, 2024

An analyst waxed bullish on the company's leading pipeline program.

Via The Motley Fool

Is Viking Therapeutics Stock a Buy? ↗

September 29, 2024

The company is in the spotlight for one of its programs, but it's got others that also have promise.

Via The Motley Fool

Better Rising Biotech: Viking Therapeutics vs. Summit Therapeutics ↗

September 28, 2024

One of them is performing much better than the other this year.

Via The Motley Fool

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.